The DUO-O trial, which assessed the use of durvalumab in combination with platinum-based chemotherapy and bevacizumab in patients with advanced ovarian cancer, showed that immunotherapy combined with chemotherapy and targeted therapy benefited patients irrespective of their BRCA1/BRCA2 DNA repair-associated (BRCA1/2) mutational status.19 Here, BRCA2 is linked to ovarian carcinoma.